New Haven, CT – According to filings with the U.S. Securities and Exchange Commission, Cybrexa Therapeutics is raising $29,923,348.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Per Hellsund played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cybrexa Therapeutics

Cybrexa was founded by physician-scientists and an experienced management team that has built numerous successful life sciences ventures. We are an oncology-focused platform technology company that enables antigen-independent targeting of tumors and metastases with deep tissue penetration for small molecule anti-cancer drugs. We’re passionate about bringing new treatment options to help more cancer patients live longer, more fulfilling lives. Cybrexa alphalex is a tumor targeting platform that powers new applications and combinations of existing cancer therapeutics. Using an elegant approach for targeted intracellular drug delivery independent of surface antigens, alphalex selectively delivers powerful anticancer agents directly into tumor cells.

To learn more about Cybrexa Therapeutics, visit http://www.cybrexa.com/

Contact:
Per Hellsund, Chief Executive Officer
860-876-0380
https://www.linkedin.com/in/per-hellsund-860b20b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved